Lara Longpre - Jan 6, 2022 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
Chief Development Officer
Signature
/s/ Jody Howe, Attorney-in-Fact
Stock symbol
MIRM
Transactions as of
Jan 6, 2022
Transactions value $
$0
Form type
4
Date filed
1/7/2022, 03:53 PM
Previous filing
Nov 15, 2021
Next filing
May 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Award $0 +10K +11.76% $0.00 95K Jan 6, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Stock Option (right to buy) Award $0 +60K $0.00 60K Jan 6, 2022 Common Stock 60K $15.87 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan.
F2 1/4th of the shares vest one year after January 6, 2022 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.